Small Volume Parenteral Market - Comprehensive Industry Analysis & Forecast

Small Volume Parenteral Market Synopsis

Small Volume Parenteral Market Size Was Valued at USD 297.59 Billion in 2023 and is Projected to Reach USD 580.18 Billion by 2032, Growing at a CAGR of 7.7 % From 2024-2032.

The Small Volume Parenteral (SVP) Market is defined as the segment of the industry involved in manufacturing and distribution of small volumes of parenteral solutions which are administered directly into the body in quantities not more than 100 millilitres. SVPs occupy a special place in the healthcare system because they are a way to provide medications that are rapidly absorbed and to target delivery of which it is important to adjust the dosage, used in clinics, hospitals, and home care. These are analgesic, antibiotics, vaccines and biologics, and electrolyte solutions, and can be given through the intravenous (IV), intramuscular (IM) or subcutaneous routes. The market drivers for SVPs include the increasing rate of chronic diseases, innovation in biotechnology and an ageing population whose medical condition demands constant attention. the possibilities of contamination.

The Small Volume Parenteral (SVP) Market is on the growth path and the factors that influence this market include increased incidences of chronic diseases which has enhanced the development of biopharmaceuticals and, also due to the demands several specialty medicines that require accurate and speedy distribution. SVP that pertains to injections in which the volumes of medications in the container cannot exceed a hundred millilitres are highly useful in hospital, clinics and home healthcare due to their efficiency in delivering medications in the bloodstream or muscle in a faster manner than any other orthodox method. The increasing population of the ageing group, who for one have chronic health conditions that would need constant attention, are also propelling the demand for SVPs.

Moreover, with advanced diseases like cancer, diabetes, and cardiovascular diseases the use of SVP’s have become inevitable for administering biologics and pain management drugs, electrolytes, and vaccines as important for management of chronic illnesses. Improvement in the packaging and drug delivery systems through the use of technologies is making SVPs more convenient, safe, and efficient, thus stimulating growth of the market. For example, prefilled syringes, single-dose vials, and autoinjectors have been established in terms of patient convenience, given that an increasing number of patients monitor diseases at home.

Small Volume Parenteral Market Trend Analysis:

Shift Toward Self-Administration and Home Healthcare

• A prominent factor defining the emergence of new entrants in Small Volume Parenteral (SVP) Market is self-administration and home healthcare industry that offers easy and flexible way to get treatment with least medical intervention. Given the rising costs of healthcare delivery and changing patient preferences and complexity of patients’ conditions, patients with chronic diseases of diabetes, rheumatoid arthritis, and cardiovascular diseases prefer to stay at home instead of visiting hospitals frequently. This has resulted in the need to develop SVPs in the more user-centric delivery systems like the pre-filled syringes, auto-injectors and wearable infusers, where the patient is able to give the doses independently, safely and efficaciously. To meet this growing market demand, pharmaceutical players are introducing SVP products that are convenient, lightweight and safe. Over the counter devices have benefited from new features such as single use, disposable and tamper proof, meaning patients can control their health issues from home.

Expansion into Emerging Markets as a Key Growth Opportunity

• The new markets in the emerging economies can considerably contribute to the development of the Small Volume Parenteral (SVP) Market, offering stakeholders in both manufacturing and healthcare essential growth prospects. The Asian and Pacific region, Latin America, some African countries are currently showing considerable progress in the development of health care services and higher levels of concern towards health care spending that will make the SVP products to gain favorable environment to penetrate into. These regions are also having increased rates of diseases such diabetes, cancer, cardiovascular diseases and therefore, there is increased need for injectable treatments which provide long?lasting, localized relief. These diseases are increasingly reported within the global population, yet few effective treatments have been developed for these conditions, placing a huge bargain at stake for high quality and cheap SVPs. Political and regulatory authorities of such regions remain interested in providing citizens with affordable and effective medicines, enhancing their quality, and developing local production of critical goods, which became possible for SVP manufacturers to set their production facilities or search for strategic partners to optimize regional distribution channels.

Small Volume Parenteral Market Segment Analysis:

Small Volume Parenteral Market is Segmented on the basis of form, dosage type, end user, and region.

By Form, the Liquid segment is expected to dominate the market during the forecast period

• The liquid segment will be a market leader in the forecast period. The preference for liquid formulations in SVPs relates primarily to convenience of application, fast rate of diffusion, and ability to deliver the active ingredient into the veins or muscle tissue. These formulations are particularly valuable for products where the effect and speed of release are critical, including analgesic, antibiotics, and emergency drugs. Liquid SVPs are also easier to prepare, stow, and disburse as opposed to other forms such as lyophilized powders; therefore, both MSOs and health care suppliers can leverage. The growing application of liquid SVPs for new enforcement in hospitals, clinic, and home healthcare aid also bolster the dominance of this segment as the healthcare professionals and patients prefer ready to use formulation. Also, liquids in pre-filled syringes, vials as well as ampoules enhance patient convenience coupled with safety in that there is reduced chance of wrong measurements as well as contamination.

By Dosage Type, Single-Dose segment expected to held the largest share

• The single-dose segment will be expected to dominate during the projected years. SVPs given as single-dose products have gained popularity, therefore, based on its convenience, safety, and getting rid of handling multi-dose vial risk for contamination particularly for injectable products. These formulations enable the responding healthcare providers to provide accurate, single administration of drugs in an attempt to reduce dosing confusion and deliberate the best treatment plans. Single-dose SVP is most suitable in hospitals and emergency usage where the accuracy and speeds of the dosing is core. Further, it accrues in vaccination programmes, antibiotics and emergency drugs where single dose application is more prevalent.

Small Volume Parenteral Market Regional Insights:

North America is Expected to Dominate the Market Over the Forecast period

• The Small Volume Parenteral (SVP) Market is likely to gain impressive growth in North America throughout the forecast period due to a well-established healthcare system, increased expenditure on healthcare services, and growing cases of chronic diseases. The level of adoption of innovative treatment methods and injectable therapies is high in the region due to the strong history of the medical industry in the region and people’s needs for SVPs. In particular, the United States and Canada have a sizable and still-growing pool of patients with chronic diseases, including diabetes, cancer, and cardiovascular diseases who require constant maintenance and injections.
• In addition, due to North America having very developed legislation, the quality of drugs produced is high, therefore SVP products adhere to maximum safety and quality standards. The healthcare systems of the region are expecting more user-friendly SVPs such as pre-filled syringing and auto injector due to the enhancement of patient convenience and care quality. This is because more and more patients require flexibility in the treatment procedures, and this has shifted them to home healthcare healthcare that can be self-administered. Commitments to healthcare enhancements and an enhanced funding for antimicrobial stewardship plus scaled-up immunization activities add to the demand for SVPs.

Active Key Players in the Small-Volume Parenteral Market:

• AbbVie Inc. (United States)
• Amgen Inc. (United States)
• AstraZeneca PLC (United Kingdom)
• B. Braun Melsungen AG (Germany)
• Baxter International Inc. (United States)
• Fresenius Kabi AG (Germany)
• GlaxoSmithKline plc (United Kingdom)
• Hikma Pharmaceuticals PLC (United Kingdom)
• Johnson & Johnson (United States)
• Novartis AG (Switzerland)
• Otsuka Pharmaceutical Co., Ltd. (Japan)
• Pfizer Inc. (United States)
• Roche Holding AG (Switzerland)
• Sanofi S.A. (France)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Other Active Players

Key Industry Developments in the Small-Volume Parenteral Market:

In September 2023, Pharmaceutical company Amneal Pharmaceuticals, Inc. declared that the U.S. Food and Drug Administration ("FDA") had approved its Abbreviated New Drug Application ("ANDA") for calcium gluconate in sodium chloride injection, 1000 2000 mg/100 mL and mg/50 mL.